Momelotinib in Myelofibrosis Patients With Thrombocytopenia: Post Hoc Analysis From Three Randomized Phase 3 Trials

Momelotinib in Myelofibrosis Patients With Thrombocytopenia: Post Hoc Analysis From Three Randomized Phase 3 Trials

The oral activin A receptor type I, Janus kinase 1 (JAK1), and JAK2 inhibitor momelotinib demonstrated symptom, spleen, and anemia benefits in intermediate- and high-risk myelofibrosis (MF). Post hoc analyses herein evaluated the efficacy and safety of momelotinib in patients with MF and thrombocyto...

Cur síos iomlán

Sonraí bibleagrafaíochta
Príomhchruthaitheoirí:	Jean-Jacques Kiladjian, Alessandro M. Vannucchi, Aaron T. Gerds, Vikas Gupta, Srdan Verstovsek, Miklos Egyed, Uwe Platzbecker, Jiří Mayer, Sebastian Grosicki, Árpád Illés, Tomasz Woźny, Stephen T. Oh, Donal McLornan, Ilya Kirgner, Sung-Soo Yoon, Claire N. Harrison, Barbara Klencke, Mei Huang, Jun Kawashima, Ruben Mesa
Formáid:	Alt
Teanga:	English
Foilsithe / Cruthaithe:	Wiley 2023-11-01
Sraith:	HemaSphere
Rochtain ar líne:	http://journals.lww.com/10.1097/HS9.0000000000000963

Míreanna comhchosúla

Clinical outcomes of patients with myelofibrosis after immediate transition to momelotinib from ruxolitinib
de réir: Ruben Mesa, et al.
Foilsithe / Cruthaithe: (2023-06-01)

Changes in bone marrow fibrosis during momelotinib or ruxolitinib therapy do not correlate with efficacy outcomes in patients with myelofibrosis
de réir: Stephen T. Oh, et al.
Foilsithe / Cruthaithe: (2024-02-01)

Symptomatic benefit of momelotinib in patients with myelofibrosis: results from the SIMPLIFY phase III studies
de réir: Mesa, RA, et al.
Foilsithe / Cruthaithe: (2023)

Symptomatic benefit of momelotinib in patients with myelofibrosis: Results from the SIMPLIFY phase III studies
de réir: Ruben A. Mesa, et al.
Foilsithe / Cruthaithe: (2023-05-01)

MOMENTUM: momelotinib vs danazol in patients with myelofibrosis previously treated with JAKi who are symptomatic and anemic
de réir: Verstovsek, S, et al.
Foilsithe / Cruthaithe: (2021)

S195: MOMENTUM: PHASE 3 RANDOMIZED STUDY OF MOMELOTINIB (MMB) VERSUS DANAZOL (DAN) IN SYMPTOMATIC AND ANEMIC MYELOFIBROSIS (MF) PATIENTS PREVIOUSLY TREATED WITH A JAK INHIBITOR
de réir: S. Verstovsek, et al.
Foilsithe / Cruthaithe: (2022-06-01)

P1050: THROMBOCYTOPENIC MYELOFIBROSIS (MF) PATIENTS PREVIOUSLY TREATED WITH A JAK INHIBITOR IN A PHASE 3 RANDOMIZED STUDY OF MOMELOTINIB (MMB) VERSUS DANAZOL (DAN) [MOMENTUM]
de réir: A. Vannucchi, et al.
Foilsithe / Cruthaithe: (2022-06-01)

Momelotinib: an emerging treatment for myelofibrosis patients with anemia
de réir: Helen T. Chifotides, et al.
Foilsithe / Cruthaithe: (2022-01-01)

Evaluating the Safety, Efficacy, and Therapeutic Potential of Momelotinib in the Treatment of Intermediate/High-Risk Myelofibrosis: Evidence to Date
de réir: Bassiony S, et al.
Foilsithe / Cruthaithe: (2020-09-01)

A phase 1/2, open-label study evaluating twice-daily administration of momelotinib in myelofibrosis
de réir: Vikas Gupta, et al.
Foilsithe / Cruthaithe: (2017-01-01)

P1044: REDUCTION IN RED BLOOD CELL TRANSFUSION BURDEN: A NOVEL LONGITUDINAL TIME-DEPENDENT ANALYSIS IN PATIENTS WITH TRANSFUSION-DEPENDENT MYELOFIBROSIS TREATED WITH MOMELOTINIB
de réir: Claire Harrison, et al.
Foilsithe / Cruthaithe: (2023-08-01)

P1062: INDIRECT TREATMENT COMPARISON OF MOMELOTINIB VS FEDRATINIB SAFETY IN PATIENTS WITH MYELOFIBROSIS
de réir: Francesca Palandri, et al.
Foilsithe / Cruthaithe: (2023-08-01)

P1057: INDIRECT TREATMENT COMPARISONS OF MOMELOTINIB VS PACRITINIB SAFETY AND ANEMIA OUTCOMES IN PATIENTS WITH MYELOFIBROSIS
de réir: Lucia Masarova, et al.
Foilsithe / Cruthaithe: (2023-08-01)

Retrospective analysis of pacritinib in patients with myelofibrosis and severe thrombocytopenia
de réir: Srdan Verstovsek, et al.
Foilsithe / Cruthaithe: (2021-09-01)

P1069: RETROSPECTIVE COMPARISON OF PATIENT OUTCOMES ON PACRITINIB VERSUS RUXOLITINIB IN PATIENTS WITH MYELOFIBROSIS AND THROMBOCYTOPENIA
de réir: C. Harrison, et al.
Foilsithe / Cruthaithe: (2022-06-01)

<i>Erratum</i> to: Retrospective analysis of pacritinib in patients with myelofibrosis and severe thrombocytopenia
de réir: Srdan Verstovsek, et al.
Foilsithe / Cruthaithe: (2024-04-01)

Momelotinib – a promising advancement in the management of myelofibrosis in adults with anemia
de réir: Muhammad Furqan, et al.
Foilsithe / Cruthaithe: (2024-06-01)

PB2183: TRANSFUSION-RELATED COST OFFSETS AND TIME BURDEN IN PATIENTS WITH MYELOFIBROSIS (MF) TREATED WITH MOMELOTINIB (MMB) VS DANAZOL (DAN)
de réir: Lucia Masarova, et al.
Foilsithe / Cruthaithe: (2023-08-01)

Momelotinib in myelofibrosis and beyond: a comprehensive review of therapeutic insights in hematologic malignancies
de réir: Parisa alsadat Dadkhah, et al.
Foilsithe / Cruthaithe: (2024-08-01)

Patient-reported Outcomes and Quality of Life in Anemic and Symptomatic Patients With Myelofibrosis: Results From the MOMENTUM Study
de réir: Ruben A. Mesa, et al.
Foilsithe / Cruthaithe: (2023-11-01)

Allogeneic stem cell transplantation for myelofibrosis in 2012.
de réir: McLornan, D, et al.
Foilsithe / Cruthaithe: (2012)

State-of-the-art review: allogeneic stem cell transplantation for myelofibrosis in 2019
de réir: Donal P. McLornan, et al.
Foilsithe / Cruthaithe: (2019-04-01)

Momelotinib for myelofibrosis: our 14 years of experience with 100 clinical trial patients and recent FDA approval
de réir: Ayalew Tefferi, et al.
Foilsithe / Cruthaithe: (2024-03-01)

JAK Inhibition for the Treatment of Myelofibrosis: Limitations and Future Perspectives
de réir: Prithviraj Bose, et al.
Foilsithe / Cruthaithe: (2020-08-01)

P1037: DOES EARLY INTERVENTION IN MYELOFIBROSIS IMPACT OUTCOMES? A POOLED ANALYSIS OF THE COMFORT I AND II STUDIES
de réir: C. Harrison, et al.
Foilsithe / Cruthaithe: (2022-06-01)

Long-term treatment with pacritinib on a compassionate use basis in patients with advanced myelofibrosis
de réir: Claire Harrison, et al.
Foilsithe / Cruthaithe: (2023-01-01)

Calr type 1/like mutation in myelofibrosis is the most prominent predictor of momelotinib drug survival and longevity without transplant
de réir: Ayalew Tefferi, et al.
Foilsithe / Cruthaithe: (2024-03-01)

Ten years of treatment with ruxolitinib for myelofibrosis: a review of safety
de réir: Srdan Verstovsek, et al.
Foilsithe / Cruthaithe: (2023-07-01)

S167: EFFICACY AND SAFETY OF LUSPATERCEPT FOR THE TREATMENT OF ANEMIA IN PATIENTS WITH MYELOFIBROSIS: RESULTS FROM THE ACE-536-MF-001 STUDY
de réir: Aaron T. Gerds, et al.
Foilsithe / Cruthaithe: (2023-08-01)

PB2232: A RANDOMIZED, CONTROLLED CLINICAL TRIAL (PHASE 2B) OF NS-018 VERSUS BEST AVAILABLE THERAPY IN SUBJECTS WITH PRIMARY OR SECONDARY MYELOFIBROSIS WITH SEVERE THROMBOCYTOPENIA
de réir: Melisa Palacio, et al.
Foilsithe / Cruthaithe: (2023-08-01)

Long-term treatment with pacritinib on a compassionate use basis in patients with advanced myelofibrosis
de réir: Harrison, C, et al.
Foilsithe / Cruthaithe: (2023)

The effect of eltrombopag in managing thrombocytopenia associated with tyrosine kinase therapy in patients with chronic myeloid leukemia and myelofibrosis
de réir: Mahran Shoukier, et al.
Foilsithe / Cruthaithe: (2020-09-01)

Momelotinib (JAK1/JAK2/ACVR1 inhibitor): mechanism of action, clinical trial reports, and therapeutic prospects beyond myelofibrosis
de réir: Ayalew Tefferi, et al.
Foilsithe / Cruthaithe: (2023-03-01)

Determinants of survival and retrospective comparisons of 183 clinical trial patients with myelofibrosis treated with momelotinib, ruxolitinib, fedratinib or BMS- 911543 JAK2 inhibitor
de réir: Naseema Gangat, et al.
Foilsithe / Cruthaithe: (2023-01-01)

Fedratinib Improves Myelofibrosis-related Symptoms and Health-related Quality of Life in Patients with Myelofibrosis Previously Treated with Ruxolitinib: Patient-reported Outcomes from the Phase II JAKARTA2 Trial
de réir: Claire N. Harrison, et al.
Foilsithe / Cruthaithe: (2021-05-01)

Momelotinib: Mechanism of action, clinical, and translational science
de réir: Georgios Vlasakakis, et al.
Foilsithe / Cruthaithe: (2024-08-01)

P1018: UPDATED RESULTS FROM MANIFEST ARM 2: EFFICACY AND SAFETY OF PELABRESIB (CPI-0610) AS ADD-ON TO RUXOLITINIB IN MYELOFIBROSIS
de réir: Marina Kremyanskaya, et al.
Foilsithe / Cruthaithe: (2023-08-01)

Bone marrow fibrosis in myelofibrosis: pathogenesis, prognosis and targeted strategies
de réir: Abdallah Abou Zahr, et al.
Foilsithe / Cruthaithe: (2016-06-01)

Treating Anemic Patients With Myelofibrosis in the New Janus Kinase Inhibitor Era: Current Evidence and Real-world Implications
de réir: Aaron T. Gerds, et al.
Foilsithe / Cruthaithe: (2022-10-01)

A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis
de réir: Alessandro M. Vannucchi, et al.
Foilsithe / Cruthaithe: (2015-09-01)